Loading...
Aldosterone does not predict cardiovascular events following acute coronary syndrome in patients initially without heart failure
Pitts, Reynaria Gunzburger, Elise Ballantyne, Christie M. Barter, Philip J. Kallend, David Leiter, Lawrence A. Leitersdorf, Eran Nicholls, Stephen J. Shah, Prediman K. Tardif, Jean-Claude
Pitts, Reynaria
Gunzburger, Elise
Ballantyne, Christie M.
Barter, Philip J.
Kallend, David
Leiter, Lawrence A.
Leitersdorf, Eran
Nicholls, Stephen J.
Shah, Prediman K.
Tardif, Jean-Claude
Abstract
Background-—Aldosterone may have adverse effects in the myocardium and vasculature. Treatment with an aldosterone antagonist reduces cardiovascular risk in patients with acute myocardial infarction complicated by heart failure (HF) and left ventricular systolic dysfunction. However, most patients with acute coronary syndrome do not have advanced HF. Among such patients, it is unknown whether aldosterone predicts cardiovascular risk. Methods and Results-—To address this question, we examined data from the dal-OUTCOMES trial that compared the cholesteryl ester transfer protein inhibitor dalcetrapib with placebo, beginning 4 to 12 weeks after an index acute coronary syndrome. Patients with New York Heart Association class II (with LVEF
Keywords
acute coronary syndrome, aldosterone, morbidity/mortality
Date
2017
Type
Journal article
Journal
Journal of the American Heart Association
Book
Volume
6
Issue
1
Page Range
1-7
Article Number
ACU Department
Collections
Relation URI
Source URL
Event URL
Open Access Status
Published as ‘gold’ (paid) open access
License
File Access
Controlled
Notes
© 2017 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is
non-commercial and no modifications or adaptations are made.